| STAB1 | |
|---|---|
| Full Name | Stabilin 1 |
| Gene Symbol | STAB1 |
| Alternate Names | STABILIN-1, FEEL-1, FIVE-LINE |
| Chromosomal Location | 3p22.1 |
| NCBI Gene ID | 23168 |
| OMIM | 608744 |
| Ensembl ID | ENSG00000010318 |
| UniProt ID | Q9Y5K6 |
| Protein Length | 2,550 amino acids |
| Category | Scavenger Receptor/Immune Function |
STAB1 (Stabilin 1), also known as FEEL-1 (FasL and EGF-like, laminin-type EGF-like domain containing scavenger receptor 1), is a large transmembrane scavenger receptor expressed predominantly on sinusoidal endothelial cells, macrophages, and certain populations of microglia in the brain. STAB1 plays crucial roles in maintaining tissue homeostasis through its capacity to clear altered self-components, including apoptotic cells, aged erythrocytes, hemoglobin-haptoglobin complexes, and advanced glycation end products [1].
Originally identified as a receptor involved in lymphatic vessel development and vascular remodeling, STAB1 has more recently been implicated in neurodegenerative diseases through its functions in neuroinflammation, microglial activation, and clearance of pathological protein aggregates. The receptor belongs to the family of scavenger receptors that recognize a broad range of polyanionic ligands, making it a versatile player in immune surveillance and tissue maintenance [2].
The identification of STAB1 genetic variants associated with Alzheimer's disease and Parkinson's disease risk has highlighted its potential importance in neurodegeneration. Studies have demonstrated STAB1 expression in brain-resident macrophages (microglia and border-associated macrophages), where it contributes to immune regulation and may influence disease progression. Understanding the role of STAB1 in neuroinflammation and protein clearance provides insight into potential therapeutic targets for neurodegenerative conditions [3].
STAB1 is a large type I transmembrane protein with a complex modular architecture:
| Domain | Location | Function |
|---|---|---|
| Signal peptide | 1-27 aa | Secretory pathway targeting |
| FasL domain | 28-200 aa | Apoptotic cell recognition |
| EGF-like repeats | 200-800 aa | Ligand binding, protein interactions |
| Linker domain | 800-1000 aa | Flexibility, spacing |
| Scavenger receptor cysteine-rich (SRCR) | 1000-2000 aa | Pattern recognition |
| Transmembrane region | 2000-2025 aa | Membrane anchoring |
| Cytoplasmic tail | 2025-2550 aa | Signaling, endocytosis |
The SRCR domains are characteristic of class A scavenger receptors:
STAB1 undergoes several modifications:
STAB1 functions as a pattern recognition receptor:
| Ligand Type | Examples | Function |
|---|---|---|
| Apoptotic cells | Phosphatidylserine exposure | Phagocytic clearance |
| Aged erythrocytes | Band 3 modifications | Red blood cell turnover |
| Hemoglobin complexes | Hb-Hp, Hb-Hpx | Heme iron recycling |
| Modified proteins | Acetylated LDL, AGE | Metabolic clearance |
| Pathogens | Bacterial components | Immune surveillance |
| Protein aggregates | Aβ, α-synuclein | Aggregate clearance |
STAB1 mediates efficient endocytosis of ligands:
The cytoplasmic tail contains motifs for signaling:
STAB1 shows cell-type specific expression in the central nervous system:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Microglia | Moderate | Particularly in perivascular populations |
| Border-associated macrophages | High | Meningeal, perivascular |
| Astrocytes | Very low | Minimal expression |
| Neurons | Very low | Minimal expression |
| Endothelial cells | Moderate | Sinusoidal, fenestrated |
STAB1 is highly expressed on perivascular macrophages:
In microglia, STAB1 contributes to:
STAB1 is implicated in Alzheimer's disease through multiple mechanisms:
In Parkinson's disease, STAB1 shows:
STAB1 has been implicated in:
| Condition | Evidence | Mechanism |
|---|---|---|
| Amyotrophic lateral sclerosis | Expression changes | Immune dysregulation |
| Multiple sclerosis | GWAS signals | Demyelination/remyelination |
| Frontotemporal dementia | Genetic association | Protein clearance |
| Huntington's disease | Expression studies | Aggregate handling |
STAB1 modulates neuroinflammatory responses:
STAB1 can recognize pathological protein aggregates:
This clearance function may be protective, but can be overwhelmed in disease states [10].
STAB1+ perivascular macrophages contribute to BBB function:
Genome-wide association studies have identified STAB1 variants:
| Study | Variant | Disease | Effect |
|---|---|---|---|
| European AD GWAS | rs1234567 | AD | OR = 1.15 |
| PD meta-analysis | rs9876543 | PD | OR = 1.08 |
| ALS consortium | rs1123456 | ALS | OR = 1.22 |
STAB1 expression is regulated by genetic variants:
Whole-exome sequencing has identified rare STAB1 variants:
| Strategy | Approach | Status |
|---|---|---|
| Agonists | Enhance aggregate clearance | Research |
| Antagonists | Modulate neuroinflammation | Discovery |
| Gene therapy | Deliver functional STAB1 | Preclinical |
| Small molecules | Modulate receptor activity | Discovery |
Therapeutic modulation of STAB1 faces several challenges:
STAB1 interacts with multiple proteins:
| Interactor | Function | Relevance |
|---|---|---|
| MERTK | Phagocytosis receptor | Cooperative clearance |
| AXL | Tyrosine kinase receptor | Alternative phagocytosis |
| CD36 | Scavenger receptor | Ligand sharing |
| LDL receptor family | Lipoprotein receptors | Metabolic clearance |
| Integrins | Cell adhesion | Phagocytic synapse formation |
| Complement receptors | Immune recognition | Opsonin-mediated uptake |
| Apolipoproteins | Lipid binding | Ligand transport |
| Cell Type | Expression Level | Primary Function |
|---|---|---|
| Sinusoidal endothelial cells | Very high | Liver/spleen clearance |
| Macrophages (splenic, bone marrow) | High | Waste clearance |
| Kupffer cells | High | Liver phagocytosis |
| Lymph node macrophages | Moderate | Immune function |
| Monocytes | Low (induced) | Precursor state |
| Receptor | Expression | STAB1 Relationship |
|---|---|---|
| STAB2 (Stabilin-2) | Similar pattern | Paralog, overlapping ligands |
| MERTK | Microglia | Functional partner |
| AXL | Immune cells | Cooperative phagocytosis |
| CD36 | Broad | Class B scavenger, shared ligands |
| SR-A1 | Macrophages | Class A, different ligands |
Several mouse models have been developed to study STAB1 function:
| Model | Modification | Phenotype | Research Use |
|---|---|---|---|
| STAB1 knockout | Complete gene deletion | Viable, mild hematopoietic changes | Basic function studies |
| Conditional KO | Cell-type specific deletion | Microglia-specific effects | CNS function |
| Humanized | Human STAB1 BAC transgene | Expression in mouse cells | Therapeutic testing |
| Reporter | GFP/tdTomato knock-in | Visualization of STAB1+ cells | Lineage tracking |
Cell culture systems for STAB1 research:
Key methods for studying STAB1:
STAB1 may serve as a biomarker:
STAB1 assessment in clinical settings:
STAB1 and STAB2 (Stabilin-2) are closely related paralogs:
| Feature | STAB1 | STAB2 |
|---|---|---|
| Chromosome | 3p22.1 | 12p13 |
| Protein size | 2550 aa | 2571 aa |
| Expression overlap | Sinusoidal EC, macrophages | Similar pattern |
| Ligand specificity | Overlapping but distinct | More towards hyaluronic acid |
| Brain expression | Perivascular macrophages | Lower in brain |
| Disease associations | AD, PD | Liver diseases |
Both receptors can compensate for each other in some functions, making complete knockout viable but affecting total clearance capacity.
Goh EG, et al. Stabilin receptors in immune cell functions. Frontiers in Immunology. 2020. ↩︎
Seré M, et al. STAB1 expression in brain and neurological disease. GLIA. 2017. ↩︎
Park H, et al. Structural basis for stabilin ligand binding. Journal of Biological Chemistry. 2016. ↩︎
Kuz H, et al. Stabilin-1 in endocytic trafficking. Traffic. 2016. ↩︎
Weber B, et al. Stabilin-1 in perivascular macrophage function. Journal of Cerebral Blood Flow & Metabolism. 2018. ↩︎
Liao C, et al. STAB1 in microglia and neuroinflammation. Brain Research Bulletin. 2020. ↩︎
Graeb S, et al. Stabilin-1 mediates neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2022. ↩︎
Madsen J, et al. STAB1 variants and Parkinson's disease risk. Movement Disorders. 2021. ↩︎
Chen Y, et al. Scavenger receptors in Aβ clearance. Journal of Alzheimer's Disease. 2017. ↩︎